Analysts Offer Predictions for Climb Bio FY2029 Earnings

Climb Bio, Inc. (NASDAQ:CLYM) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of Climb Bio in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($2.73) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter.

Separately, Leerink Partners assumed coverage on shares of Climb Bio in a research report on Monday, December 2nd. They set an “outperform” rating and a $10.00 target price on the stock.

Climb Bio Stock Performance

NASDAQ CLYM opened at $1.68 on Friday. Climb Bio has a fifty-two week low of $1.65 and a fifty-two week high of $11.55. The business has a 50 day moving average of $2.18. The stock has a market cap of $112.94 million, a PE ratio of -0.79 and a beta of -0.24.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.